Antifungal agents for the treatment of systemic fungal infections in children

Paediatrics and Child Health

Volumn 15, Issue 9, 2010, Pages 603-608

  Allen, U D ^a  

^a CANADIAN PAEDIATRIC SOCIETY   (Canada)

Author keywords

Amphotericin B; Antifungal therapy; Echinocandins; Triazoles

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIMETABOLITE; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANEMIA; CANDIDIASIS; CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG MECHANISM; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOKALEMIA; IMMUNIZATION; INJECTION SITE REACTION; LIVER FUNCTION; LIVER TOXICITY; LUNG ASPERGILLOSIS; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; PHLEBITIS; RASH; REVIEW; SIDE EFFECT; SYSTEMIC MYCOSIS; THROMBOPHLEBITIS; TREATMENT OUTCOME; VOMITING;

EID: 78349280297     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Antachopoulos C, Walsh TJ. New agents for invasive mycoses in children. Curr Opin Pediatr 2005;17:78-87.
2. Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41:1944-8. (Pubitemid 27383233)
3. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999;18:702-8. (Pubitemid 29382466)
4. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005;24:167-74.
5. Herbrecht R, Auvrignon A, Andres E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001;20:77-82. (Pubitemid 32247101)
6. Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003;17:159-91.
7. Scarcella A, Pasquariello MB, Giugliano B, Vendemmia M, de Lucia A. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17:146-8. (Pubitemid 28096014)
8. Koren G, Lau A, Kenyon CF, Kroppert D, Klein J. Clinical course and pharmacokinetics following a massive overdose of amphotericin B in a neonate. J Toxicol Clin Toxicol 1990;28:371-8.
9. American Academy of Pediatrics. Antifungal drugs for systemic fungal infections. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book 2006 Report of the Committee on Infectious Diseases, 27th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2006:775.
10. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-66. (Pubitemid 34852563)
11. Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. E J Clin Microbiol Infect Dis 1994;13:325-9.
12. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 1997;33:52-77. (Pubitemid 27307002)
13. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant patients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-61.
14. McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2004;1:CD003850. (Pubitemid 351805355)
15. Manzoni P, Stolfi L, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Eng J Med 2007;356:2483-95.
16. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005;56:i17-i22.
17. de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998;42:404-8.
18. Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002;46:2554-63. (Pubitemid 34793463)
19. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999;24:1089-93.
20. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002;4:195-200. (Pubitemid 36142805)
21. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther 2003;25:1321-81.
22. American Academy of Pediatrics. Recommended doses of parenteral and oral antifungal drugs. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book 2006 Report of the Committee on Infectious Diseases, 27th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2006:779.
23. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-8. (Pubitemid 34214142)
24. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Eng J Med 2004;347:408-15.
25. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60.
26. Nagappan V, Deresinski S. Reviews of anti-infective agents: Posaconazole: A broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-7.
27. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am 2005;52:895-915.
28. Pannaraj PS, Walsh TJ, Baker CJ. Advances in antifungal therapy. Pediatr Infect Dis J 2005;24:921-2.
29. Isavuconazole for primary treatment of invasive apergillosis: A phase III, double blind, randomized study to evaluate safety and efficacy of isavuconazole versus voriconazole for primary treatment of invasive fungal disease caused by Apergillus species and other filamentous fungi. 〈http://clinicaltrials.gov/ct2/show/NCT00412893〉 (Accessed on September 14, 2010).
30. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In-vitro antifungal activities of isavuconazole (BAL4815), voriconazole and fluconazole against 1007 isolates of Zygomycete, Candida, Aspergillus, Fusarium and Scedosporium species. Antimicrob Agents Chemother 2008;52:1396-400. (Pubitemid 351522004)
31. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-57.
32. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Eng J Med 2002;347:2020-9. (Pubitemid 35461658)
33. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Eng J Med 2004;351:1391-402.
34. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49:3317-24. (Pubitemid 41060577)
35. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25:1110-5.
36. Chandrasekar PH, Sobel JD. Micafungin: A new echinocandin. Clin Infect Dis 2006;42:1171-8.
37. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16. (Pubitemid 39518200)
38. Vazquez JA, Sobel JD. Anidulafungin: A novel echinocandin. Clin Infect Dis 2006;43:215-22.
39. Grasela TH Jr, Goodwin SD, Walawander MK, Cramer RL, Fuhs DW, Moriarty VP. Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 1990;10:342-8.
40. David N, Gilbert MD. Sanford Guide to Antimicrobial Therapy 2009, 39th edn. Sperryville: Antimicrobial Therapy, 2009.